Highlights

• Proteomics International Laboratories rose 3.23% to 16.0 cents on Wednesday 19 August 2026.

• No price-sensitive announcement was lodged with the ASX in the days before Wednesday's move.

• The most commercially significant announcement of 2026 came on 22 July, when Proteomics told the market it had signed a national distribution agreement with pathology group Healius.

• The near-term diary points to the September quarter Appendix 4C, due in late October 2026, which will show the cash position, whether the R&D rebate has landed and whether the Burn Rate has moderated.

Proteomics International Laboratories rose 3.23% to 16.0 cents on Wednesday 19 August 2026. The headline percentage is the least interesting thing about it. Just 28,980 shares changed hands by the 15:17 AEST snapshot - a relative Volume reading of 0.23, meaning turnover was running at roughly a quarter of the stock's usual pace. At 16 cents, that entire day's trade was worth a little over $4,600. In a company capitalised at $26.

What is driving the move

No price-sensitive announcement was lodged with the ASX in the days before Wednesday's move. Proteomics' most recent filing of any kind was on 13 August 2026 - a price-sensitive release confirming an Australian Patent for PromarkerEndo, its endometriosis test - and nothing has followed it. There is no verified company-specific catalyst for the 19 August gain. It is worth noting that this pattern is familiar to Proteomics.

Recent developments and operating picture

The most commercially significant announcement of 2026 came on 22 July, when Proteomics told the market it had signed a national distribution agreement with pathology group Healius. Under the agreement, Healius becomes the exclusive Australian pathology distribution partner for the Promarker portfolio for an initial three-year term, with a mutual option to extend for a further three years. Proteomics retains laboratory testing, clinical reporting and quality and regulatory responsibility; Healius takes on specimen collection, referrer engagement and market access. The company said implementation would begin immediately, with a phased commercial rollout planned during FY27.

Business, numbers and context

Proteomics International is a Perth-based diagnostics company built on proteomics - the study of proteins in blood. Its lead product, PromarkerD, is a predictive blood test intended to identify people with type 2 diabetes who are at elevated risk of developing chronic kidney disease before conventional clinical indicators such as declining kidney function become apparent. The commercial logic is prevention: identify at-risk patients early enough for intervention to change the outcome. Around that sits a pipeline using the same platform - PromarkerEndo for endometriosis, a condition notorious for diagnostic delay, and PromarkerEso for oesophageal adenocarcinoma.

Opportunity and risks

The bull case is straightforward. Proteomics owns patented tests addressing three large, poorly served clinical problems, and in Healius it has now secured a national distribution partner with the collection-centre footprint and referrer relationships a $26 million company could never build alone. If PromarkerD achieves meaningful clinical uptake and, eventually, reimbursement, the addressable market is large relative to the company's present valuation, and diagnostics businesses scale with very high incremental margins once volume arrives. Funding is the first, second and third risk.

What comes next

The near-term diary points to the September quarter Appendix 4C, due in late October 2026, which will show the cash position, whether the R&D rebate has landed and whether the burn rate has moderated. Between now and then, the questions are whether Proteomics raises Capital and on what terms, and whether the Healius rollout produces...

Bottom line

Wednesday's 3% gain is not a story - 29,000 shares at a quarter of normal volume is noise, and no announcement supports it. The real story is the gap between Proteomics' strategic progress and its financial position.